Jiuzhitang (000989.SZ) Holding Subsidiary Develops New Drugs and Starts Phase IIb Clinical Trials

Zhitongcaijing · 2d ago

Zhitong Finance App News, Jiuzhitang (000989.SZ) announced that on November 13, 2026, the company's holding subsidiary Jiuzhitang Aesthetic (Beijing) Cell Technology Co., Ltd. (“Beijing Ameke”) and the clinical trial lead unit Guangzhou Medical University First Affiliated Hospital organized a “multi-center, randomized, double-blind, placebo-controlled phase IIb clinical trial to evaluate the efficacy and safety of human bone marrow mesenchymal stem cell (hBMMSc) injection in the treatment of autoimmune alveolar proteinosis (aPAP)”.

The drug used in clinical trials is a human bone marrow mesenchymal stem cell (HBMMSc) injection. It is registered as a Class 1 new drug, and the drug registration classification is a therapeutic biological product. The application for this drug is autoimmune alveolar proteinosis (aPAP). The stem cell product used in this clinical trial is a human bone marrow mesenchymal stem cell (HBMMSc) injection, independently developed and produced by Beijing Meike.